The Prolactin Inducible Protein Modulates Antitumor Immune Responses and Metastasis in a Mouse Model of Triple Negative Breast Cancer
The prolactin inducible protein (PIP) is expressed to varying degrees in more than 90% of breast cancers (BCs). Although high levels of PIP expression in BC has been shown to correlate with better prognosis and patient response to chemotherapy, some studies suggest that PIP may also play a role in m...
Main Authors: | Chidalu A. Edechi, Nnamdi M. Ikeogu, Gloria N. Akaluka, Lucas E. L. Terceiro, Mikayla Machado, Enitan S. Salako, Aida F. Barazandeh, Sam K. P. Kung, Jude E. Uzonna, Yvonne Myal |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.639859/full |
Similar Items
-
Regulation of Immunity in Breast Cancer
by: Chidalu A. Edechi, et al.
Published: (2019-07-01) -
Metastasis: A Bane of Breast Cancer Therapy
by: Chidalu A. Edechi,, et al.
Published: (2020-09-01) -
The Breast Tumor Microenvironment: A Key Player in Metastatic Spread
by: Lucas E. L. Terceiro, et al.
Published: (2021-09-01) -
<i>Leishmania</i> Immunity: Advancing Immunotherapy and Vaccine Development
by: Nnamdi M. Ikeogu, et al.
Published: (2020-08-01) -
Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases
by: Lucas E. L. Terceiro, et al.
Published: (2023-07-01)